-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Cormedix, Raises Price Target to $14

Benzinga·11/10/2026 10:34:59
Listen to the news
Needham analyst Serge Belanger maintains Cormedix (NASDAQ:CRMD) with a Buy and raises the price target from $12 to $14.